Zelger B
Dermatohistopathologisches Labor, Universitätsklinik für Dermatologie, Universität Innsbruck, Osterreich.
Verh Dtsch Ges Pathol. 1998;82:290-300.
A new unifying concept of fibrohistiocytic skin lesions.
Retrospective clinicopathologic study of more than 2,000 dermatofibromas (DF) recruited over the last two decades.
As the least common denominator all DF show a reactive fibrohistiocytic tissue response with variable epidermal hyperplasia, peripheral sclerosis and peripherally accentuated lymphohistiocytic tissue response. The histological, immunohistochemical and ultrastructural profile varies according to the time cycle as well as the fibro-myofibrohistiocytic differentiation of the lesions. From a conceptual point of view such lesions are best grouped into three categories: 1. DF with cellular/stromal pecularities. All classic variants, from the first description by Unna in 1894 to lesions described in 1978, namely DF, (benign) fibrous histiocytoma, histiocytoma cutis, sclerosing hemangioma, nodular subepidermal fibrosis or fibrous xanthoma, fall into this category; moreover, many of the clinicopathologic variants described over the last two decades such as granular cell, clear cell, myofibroblastic, sclerosing, monster cells, atypical ("pseudosarcomatous"), haemosiderotic ("elusive"), cholesterotic, and myxoid variants. 2. DF with architectural pecularities such as deep penetrating, atrophic, aneurysmal ("angiomatoid"), haemangiopericytoma-like, palisading and ossifying variants. And 3. DF with both cellular/stromal and architectural pecularities including those with a homogenous mixture of components as seen in epithelioid, cellular benign variants, smooth muscle proliferation in DF, multinucleate cell angiohistiocytoma, cellular neurothekeoma, and dermal plexiform fibrohistiocytic tumour; as well as those with heterogeneous mixture of components in composite or mixed dermatofibromas.
DF is common, the clinicopathological variability manyfold, and their misinterpretation as malignancy such as dermatofibrosarcoma protuberans or Kaposi sarcoma not rare. Such cases have important clinical implications such as unnecessary investigations, controls and livelong anxiety of patients.
提出一种关于纤维组织细胞性皮肤病变的新统一概念。
对过去二十年间收集的2000多例皮肤纤维瘤(DF)进行回顾性临床病理研究。
作为最常见的共同特征,所有DF均表现为反应性纤维组织细胞性组织反应,伴有不同程度的表皮增生、周边硬化以及周边显著的淋巴组织细胞性组织反应。组织学、免疫组化及超微结构特征根据病变的时间周期以及纤维-肌纤维组织细胞分化情况而有所不同。从概念角度来看,此类病变最好分为三类:1. 具有细胞/基质特征的DF。所有经典变体,从1894年Unna首次描述到1978年所描述的病变,即DF、(良性)纤维组织细胞瘤、皮肤组织细胞瘤、硬化性血管瘤、结节性表皮下纤维化或纤维性黄色瘤,均属于此类;此外,过去二十年间描述的许多临床病理变体,如颗粒细胞、透明细胞、肌纤维母细胞、硬化性、怪异细胞、非典型(“假肉瘤样”)、含铁血黄素沉着(“隐匿性”)、含胆固醇及黏液样变体。2. 具有结构特征的DF,如深部浸润、萎缩性、动脉瘤样(“血管瘤样”)、血管外皮细胞瘤样、栅栏状及骨化性变体。以及3. 同时具有细胞/基质和结构特征的DF,包括那些具有成分均匀混合的病变,如上皮样、细胞性良性变体、DF中的平滑肌增生、多核细胞血管组织细胞瘤、细胞性神经鞘瘤及真皮丛状纤维组织细胞瘤;以及那些在复合性或混合性皮肤纤维瘤中具有成分异质性混合的病变。
DF很常见,临床病理变异性多样,将其误诊为恶性肿瘤如隆突性皮肤纤维肉瘤或卡波西肉瘤并不罕见。此类病例具有重要的临床意义,如不必要的检查、监测以及患者长期的焦虑。